The Effectiveness of Ovarian Cancer Screening: A Decision Analysis Model

  1. Marilyn M. Schapira, MD, MPH;
  2. David B. Matchar, MD; and
  3. Mark J. Young, MD
  1. From the Medical College of Wisconsin, Milwaukee, Wisconsin; Duke University Medical Center, Durham, North Carolina; Henry Ford Hospital, Detroit, Michigan. Requests for Reprints: Marilyn M. Schapira, MD, Section of General Internal Medicine, 5000 W. National Avenue, Clement J. Zablocki Veterans Affairs Medical Center, 111-B, Milwaukee, WI 53295-1000. Acknowledgments: The authors thank John Pauk, MD, MPH, for review of the manuscript.

    Abstract

    Objective: To estimate the effectiveness of ovarian cancer screening with CA 125 and transvaginal sonography.

    Design: Decision analysis was used to examine the no-screen compared with the screen strategy.

    Setting: Estimates of cancer incidence, survival, and life expectancy were derived from population-based data and clinical series.

    Subjects: A cohort of 40-year-old women of all races and residing in the United States.

    Interventions: A one-time screening intervention. The criterion standard for diagnosis of ovarian cancer was evaluation with exploratory laparotomy.

    Main Outcome Measure: Average years of life expectancy gained by women in the screened group.

    Results: Screening for ovarian cancer with a combination of CA 125 and transvaginal sonography increases the average life expectancy in the population by less than 1 day.

    Conclusions: Given the limited effect on overall life expectancy, it is unlikely that mass screening for ovarian cancer with CA 125 and transvaginal sonography would be an effective health policy.

    « Previous | Next Article »Table of Contents